Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 8/20 | 1.00 |
| ▸ | HTR1A | P08908 | 6/20 | 1.00 |
| ▸ | HTR1B | P28222 | 6/20 | 1.00 |
| ▸ | HTR6 | P50406 | 5/20 | 1.00 |
| ▸ | HTR2A | P28223 | 4/20 | 1.00 |
| ▸ | HTR2C | P28335 | 3/20 | 1.00 |
| ▸ | HTR7 | P34969 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | HTR4 | Q13639 | 2/20 | 1.00 |
| ▸ | HTR1E | P28566 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | HTR5A | P47898 | 2/20 | 1.00 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 1.00 |
| ▸ | HTR3B | O95264 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | HTR1F | P30939 | 1/20 | 1.00 |
| ▸ | HTR3A | P46098 | 1/20 | 1.00 |
| ▸ | MTNR1A | P48039 | 1/20 | 1.00 |
| ▸ | MTNR1B | P49286 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mebufotenin SCHEMBL27221706 | 1.00 | HTR1D (1.00) | HTR1DHTR1AHTR1BHTR6HTR2A | |
| Mebufotenin SCHEMBL31098269 | 1.00 | HTR1D (1.00) | HTR1DHTR1AHTR1BHTR6HTR2A | |
| Mebufotenin SCHEMBL132733 | 1.00 | HTR1D (1.00) | HTR1DHTR1AHTR1BHTR6HTR2A | |
| Mebufotenin SCHEMBL26111484 | 0.99 | HTR1D (0.97) | HTR1DHTR1AHTR1BHTR6HTR2A | |
| Mebufotenin SCHEMBL25330504 | 0.99 | HTR1D (0.97) | HTR1DHTR1AHTR1BHTR6HTR2A | |
| Mebufotenin SCHEMBL7205139 | 0.92 | KMT2A (1.00) | HTR1DHTR1AHTR1BHTR6HTR2A | |
| SCHEMBL8868914 | 0.92 | HTR1D (0.85) | HTR1DHTR1AHTR1BHTR6HTR2A | |
| SCHEMBL24497000 | 0.92 | SLC6A4 (1.00) | HTR1DHTR1AHTR1BHTR6HTR2A | |
| Mebufotenin SCHEMBL29992823 | 0.90 | HTR1D (0.82) | HTR1DHTR1AHTR1BHTR6HTR2A | |
| Mebufotenin SCHEMBL26120710 | 0.90 | HTR1D (0.82) | HTR1DHTR1AHTR1BHTR6HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4577245-A1 | DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY OF PSYCHEDELIC THERAPEUTICS | The Johns Hopkins University (US) | 2025-07-02 | — | — | EP | claimed |
| CN-119923278-A | Dendrimer compositions for targeted delivery of fantasy therapeutic agents | 约翰霍普金斯大学 | 2025-05-02 | — | — | CN | claimed |
| WO-2024044756-A1 | DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY OF PSYCHEDELIC THERAPEUTICS | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-02-29 | — | — | WO | claimed |
| WO-2023114529-A2 | PHARMACOACTIVE FORMULATIONS FOR DELIVERY OF PSYCHEDELIC COMPOUNDS | BENNES, INC. (US) | 2023-06-22 | — | — | WO | claimed |
| WO-2022235587-A1 | LIPID PRODRUGS OF TRYPTAMINE AND PHENETHYLAMINE PSYCHEDELICS AND USES THEREOF | TERRAN BIOSCIENCES INC. (US) | 2022-11-10 | — | — | WO | claimed |
| US-20220259147-A1 | COMPOSITION COMPRISING A BENZOATE SALT OF 5-METHOXY-N,N-DIMETHYLTRYPTAMINE | Beckley Psytech Limited (GB) | 2022-08-18 | — | — | US | claimed |
| CN-113956188-A | Synthesis method of N, N-dimethyl-5-methoxytryptamine | 河北维达康生物科技有限公司 | 2022-01-21 | — | — | CN | claimed |
| CN-122005549-A | Application of indole alkali compound in preparation of medicine or skin care product for treating or preventing skin diseases | 南京效真生物科技有限公司 | 2026-05-12 | — | — | CN | disclosed |
| WO-2026068951-A1 | 5-METHOXY-DMT FOR USE IN THE TREATMENT OF DEPRESSION | Beckley Psytech Limited (GB) | 2026-04-02 | — | — | WO | disclosed |
| EP-4712803-A1 | MIST INHALATION POD FOR DELIVERING A THERAPEUTIC | Shaheen Innovations Holding Limited (AE) | 2026-03-25 | — | — | EP | disclosed |
| US-12521370-B2 | Inhalable formulations | CYBIN UK LTD (GB) | 2026-01-13 | — | — | US | disclosed |
| EP-4654967-A1 | TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS BY PARENTERAL ADMINISTRATION OF A SINGLE, EFFECTIVE PARENTERAL DOSE OF A SHORT-ACTING PSYCHEDELIC AGENT | Cybin UK Ltd (GB) | 2025-12-03 | — | — | EP | disclosed |
| US-20250339403-A1 | Tryptamine Formulations and Uses Thereof | Natural MedTech Pty Ltd (AU) | 2025-11-06 | — | — | US | disclosed |
| WO-2022115798-A2 | COMPOSITIONS AND METHODS FOR TREATING MIGRAINE | WESANA HEALTH INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022079574-A1 | COMPOSITIONS FOR REDUCING INFLAMMATION TO IMPROVE OR MAINTAIN MENTAL OR PHYSICAL HEALTH | GOODCAP PHARMACEUTICALS LTD. (CA) | 2022-04-21 | — | — | WO | disclosed |
| CN-113979913-A | Synthesis of virus-treating medicine N, N-dimethyl-5-hydroxytryptamine-N12Method for producing oxide | 河北维达康生物科技有限公司 | 2022-01-28 | — | — | CN | disclosed |
| CN-113968810-A | Preparation method of N, N-dimethyl-5-hydroxytryptamine | 河北维达康生物科技有限公司 | 2022-01-25 | — | — | CN | disclosed |
| CN-113956188-A | Synthesis method of N, N-dimethyl-5-methoxytryptamine | 河北维达康生物科技有限公司 | 2022-01-21 | — | — | CN | disclosed |
| CN-113956188-A | Synthesis method of N, N-dimethyl-5-methoxytryptamine | 河北维达康生物科技有限公司 | 2022-01-21 | — | — | CN | disclosed |
| CN-113956188-A | Synthesis method of N, N-dimethyl-5-methoxytryptamine | 河北维达康生物科技有限公司 | 2022-01-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220259147-A1 | COMPOSITION COMPRISING A BENZOATE SALT OF 5-METHOXY-N,N-DIMETHYLTRYPTAMINE | HTR5A, SLC6A4, HTR4 | HTR1D 45/4885HTR1A 13/4885HTR1B 26/4885 |
| US-20250339403-A1 | Tryptamine Formulations and Uses Thereof | MAOA, MAOB, TPH1 | HTR1D 45/4885HTR1A 15/4885HTR1B 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.